Double-Blind, Placebo-Controlled Study of Single-Dose Amphetamine Formulations in ADHD - 02/09/11
ABSTRACT |
Objective |
To compare the efficacy and time course of single morning doses of Adderall®, extended-release, and immediate-release dextroamphetamine sulfate.
Method |
Thirty-five children with attention-deficit/hyperactivity disorder, combined type, were given Adderall, immediate-release dextroamphetamine, dextroamphetamine Spansules®, and placebo in a randomized, double-blind, crossover study. Behavior ratings, locomotor activity measurements, and academic measures were obtained over a period of 8 weeks.
Results |
All three drugs exhibited robust efficacy versus placebo on nearly all measures. The effects of dextroamphetamine Spansules were less robust in the morning, particularly compared with Adderall, but they lasted 3 to 6 hours longer, depending on the measure. Although parent behavior ratings and locomotor activity showed improvements up to 12 hours after single doses of all three drugs, the number of math problems attempted and completed correctly 4 hours after dosing were only robustly increased by Spansules.
Conclusions |
Both immediate-release amphetamines demonstrated earlier onset of effects, but dextroamphetamine Spansules showed more sustained effects that were present on a wider range of measures.
Le texte complet de cet article est disponible en PDF.Key Words : attention-deficit/hyperactivity disorder, dextroamphetamine, Adderall®, psychostimulants
Plan
| The authors appreciate the assistance of NIH Day Program teachers Anna Davidson, M.Ed., and Susan Job, M.Ed.; recreation therapist Debbie C. Marcus, C.T.R.S.; NIH Clinical Center staff members Edwina Smith, R.N., and consulting psychologist Barbara B. Keller, Ph.D. |
Vol 40 - N° 11
P. 1268-1276 - novembre 2001 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
